Cannabidiol
A non-psychoactive cannabinoid derived from the cannabis plant, approved in purified oral form for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. It is thought to exert anticonvulsant effects through several mechanisms, including modulation of ion channels and inhibition of endocannabinoid reuptake. It is also widely used as an unregulated supplement for anxiety, pain, and sleep, though clinical evidence varies.
分子量
314.5000 g/mol
LogP
6.50
TPSA
40.50 Ų
リピンスキーの五則
適合
治療領域
作用機序
Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …
2D構造
Cite this structure
Embed this structure
SMILES
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
InChI
InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
Molecular Formula
C21H30O2
HBD / HBA
2 / 2
回転可能結合数
6
重原子数
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A non-psychoactive cannabinoid derived from the cannabis plant, approved in purified oral form for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. It is thought to exert anticonvulsant effects through several mechanisms, including modulation of ion channels and inhibition of endocannabinoid reuptake. It is also widely used as an unregulated supplement for anxiety, pain, and sleep, though clinical evidence varies.
Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.
Yes, Cannabidiol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL190461. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 644019. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cannabidiol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cannabidiol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cannabidiol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cannabidiol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cannabidiol"></drugfyi-drug>